CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
| Revenue (TTM) | $328.68B |
| Gross Profit (TTM) | $12.48B |
| EBITDA | $5.30B |
| Operating Margin | 1.72% |
| Return on Equity | 107.10% |
| Return on Assets | 3.49% |
| Revenue/Share (TTM) | $1693.17 |
| Book Value | $17.46 |
| Price-to-Book | 17.82 |
| Price-to-Sales (TTM) | 0.19 |
| EV/Revenue | 0.215 |
| EV/EBITDA | 14.06 |
| Quarterly Earnings Growth (YoY) | 128.30% |
| Quarterly Revenue Growth (YoY) | 3.80% |
| Shares Outstanding | $194.56M |
| Float | $184.00M |
| % Insiders | 4.23% |
| % Institutions | 99.09% |
Volatility is currently expanding
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Cencora (COR) is transitioning from a bulk pharmaceutical distributor to a specialty medicines infrastructure provider, targeting higher-margin, service-driven growth. Recent acquisitions of OneOncology and Retina Consultants of America are driving margin expansion, with Q2 adjusted gross profit up 15.7% and margin rising to 4.31%. Management raised FY2026 adjusted EPS guidance to $17.70–$17.90, expects $3B adjusted FCF, and targets 10–14% long-term EPS growth.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 5, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer Eva C. Boratto, Executive Vice President & Chief.
COR shares are down 18% YTD, but rising EPS guidance, specialty pharma growth and strategic expansion could make this pullback worth watching.
COR's enhanced Nucleus platform targets complex specialty medication workflows, with a pilot underway across more than 20 physician practice sites.
Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. TPR, VRT, CLS and COR are some such stocks.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help specialty physician practices manage increasingly complex medication workflows with greater efficiency, visibility and control. Developed with input from customer advisory boards and specialty care providers, the updated platform combines redesigned physical infrastructure with software and interface e.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on COR and any ticker you trade — then tracks every position and per-strategy win rate.
